Emcure Pharmaceuticals Ltd Analyst Rating
based on 3 analysts
66.67%
Buy
33.33%
Hold
0.00%
Sell
Based on 3 analysts offering long term price targets for Emcure Pharmaceuticals Ltd. An average target of ₹1640
Source: S&P Global Market Intelligence
Emcure Pharmaceuticals Ltd Share analysis
Emcure Pharmaceuticals Ltd price forecast by 3 analysts
Upside of18.09%
High
₹1680
Target
₹1640.00
Low
₹1580
Emcure Pharmaceuticals Ltd target price ₹1640, a slight upside of 18.09% compared to current price of ₹1378.35. According to 3 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Emcure Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:0
Forecast
Actual
Including amortisation and stock based compensations
Emcure Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:0
Forecast
Actual
Source: S&P Global Market Intelligence
Emcure Pharmaceuticals Ltd Performance
Day's Low
Day's High
₹1,371.6₹1,415.9552 Week's Low
52 Week's High
₹1,225₹1,580
| Returns % | |
| 1 Month Return | -3.79 % |
| 3 Month Return | -0.71 % |
| 1 Year Return | + 2.18 % |
| Market Stats | |
| Previous Close | ₹1,388.80 |
| Open | ₹1,399.90 |
| Volume | 1.72L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹26,261.98Cr |
Emcure Pharmaceuticals Ltd Key Statistics
| P/E Ratio | 45.09 |
| PEG Ratio | 2.84 |
| Market Cap | ₹26,261.98 Cr |
| P/B Ratio | 0 |
| EPS | 0 |
| Dividend Yield | 0 |
| Sector | Pharmaceuticals |
| ROE | 9.01 |
Emcure Pharmaceuticals Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹26,261.98 Cr | 0.44% | 0.00 | ₹527 Cr | ₹6,658 Cr | |
| NA | ₹370.18 Cr | 56.39% | 0.74 | NA | NA | |
| BUY | ₹16,014.81 Cr | 488.49% | 0.51 | ₹314 Cr | ₹2,177 Cr | |
| NA | ₹767.60 Cr | 47.02% | 0.52 | NA | NA | |
| NA | ₹227.12 Cr | 240.73% | 0.58 | -₹12 Cr | ₹15 Cr |
Emcure Pharmaceuticals Ltd Mutual Fund Holdings
About Emcure Pharmaceuticals Ltd
Share Price: ₹1378.35 per share as on 03 Dec, 2024 04:01 PM
Market Capitalisation: ₹26,261.98Cr as of today
Revenue: ₹2,001.98Cr as on September 2024 (Q3 24)
Net Profit: ₹201.55Cr as on September 2024 (Q3 24)
Listing date: 10 Jul, 2024
| Organisation | Emcure Pharmaceuticals Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Shares Surge on Positive Upgrade - 26 Nov, 2024
Emcure Pharmaceuticals saw a significant rise in share price following an upgrade by Kotak Securities to 'Buy', with a target price of ₹1,680. The company reported strong quarterly earnings, with a 38.2% increase in net profit, driving investor confidence. The stock surged 10% during the trading session, reflecting positive market sentiment and growth prospects in the second half of FY25.Emcure Pharmaceuticals Reports Strong Q2 Earnings Growth - 08 Nov, 2024
Emcure Pharmaceuticals reported robust Q2FY25 results, with a 38.2% increase in net profit to ₹201.5 crore and a 20.4% rise in revenue to ₹2,002 crore. The strong performance was driven by growth in both domestic and international markets, particularly in Canada. Despite a slight contraction in EBITDA margins, the overall financial results reflect solid operational performance and investor confidence.Emcure Pharmaceuticals Reports Strong Q2FY25 Results - 07 Nov, 2024
Emcure Pharmaceuticals announced strong Q2FY25 results, with a 38.2% increase in PAT and 20.4% revenue growth, driven by robust international and domestic sales.Emcure Launches Subsidiary for Dermatology Expansion - 28 Oct, 2024
Emcure Pharmaceuticals has launched Emcutix Biopharmaceuticals, a wholly-owned subsidiary aimed at enhancing its dermatology portfolio. Spearheaded by G. Sathya Narayanan, the initiative targets unmet needs in the growing Indian dermatology market, valued at $1.84 billion.
Insights on Emcure Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 1.76% to 2.91% in Sep 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 1.77% to 3.30% in Sep 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 78.08% of holdings in Sep 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 1 month, EMCURE stock has moved down by -3.8%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 16.82% to 15.05% in Sep 2024 quarter
Emcure Pharmaceuticals Ltd Financials
Index Inclusions
Emcure Pharmaceuticals Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 78.08% | 0.00 | |
| Foreign Institutions | 2.91% | 65.58 | |
| Mutual Funds | 3.3% | 86.84 | |
| Retail Investors | 15.05% | ||
| Others | 0.66% |
Emcure Pharmaceuticals Ltd Key Indicators
Emcure Pharmaceuticals Ltd Valuation
Emcure Pharmaceuticals Ltd in the last 5 years
Lowest (41.68x)
November 21, 2024
Today (45.09x)
December 2, 2024
Industry (56.86x)
December 2, 2024
Highest (54.00x)
September 18, 2024
Emcure Pharmaceuticals Ltd Earnings and Dividends
Emcure Pharmaceuticals Ltd Earnings Results
Emcure Pharmaceuticals Ltd’s net profit jumped 39.83% since last year same period to ₹194.57Cr in the Q2 2024-2025. On a quarterly growth basis, Emcure Pharmaceuticals Ltd has generated 35.04% jump in its net profits since last 3-months.
Read More about Earnings Results
Emcure Pharmaceuticals Ltd Technicals Summary
Bearish
Neutral
Bullish
Emcure Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Emcure Pharmaceuticals Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Emcure Pharmaceuticals Ltd shares.
Emcure Pharmaceuticals Ltd (EMCURE) share price today is ₹1378.35
Emcure Pharmaceuticals Ltd is listed on NSE
Emcure Pharmaceuticals Ltd is listed on BSE
- Today’s highest price of Emcure Pharmaceuticals Ltd is ₹1415.95.
- Today’s lowest price of Emcure Pharmaceuticals Ltd is ₹1371.6.
PE Ratio of Emcure Pharmaceuticals Ltd is 45.09
PE ratio = Emcure Pharmaceuticals Ltd Market price per share / Emcure Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Emcure Pharmaceuticals Ltd(EMCURE) is 1.72L.
Today’s market capitalisation of Emcure Pharmaceuticals Ltd(EMCURE) is ₹26261.98Cr.
| Emcure Pharmaceuticals Ltd(EMCURE | Price |
|---|---|
52 Week High | ₹1580 |
52 Week Low | ₹1225 |
Emcure Pharmaceuticals Ltd(EMCURE) share price is ₹1378.35. It is down -12.76% from its 52 Week High price of ₹1580
Emcure Pharmaceuticals Ltd(EMCURE) share price is ₹1378.35. It is up 12.52% from its 52 Week Low price of ₹1225
| Emcure Pharmaceuticals Ltd(EMCURE | Returns |
|---|---|
1 Day Returns | -10.45% |
1 Month Returns | -3.79% |
3 Month Returns | -0.71% |
1 Year Returns | 2.18% |